Clinical Trials

Classical hematologyGastrointestinal

220 enrolled

Pathologic Complete Response, Digestive System Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Thrombocytopenia, Colorectal Neoplasms

NCT07586826 2026-05-14

N01-A-PICIT-GT

BreastClassical hematologyGynecologicThoracic

220 enrolled

Pathologic Complete Response, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Thrombocytopenia, Endometrial Neoplasms

NCT01042379 2026-05-06

I-SPY

Phase 1 Not yet recruiting

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT06743555 2026-04-28

SAVED LUNG

14 enrolled

Thoracic

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT07538206 2026-04-20

Vebectotamab Vedotin Combined With Pucotelimab in the Treatment of Locally Advanced Laryngeal Carcinoma

Phase 1/2 Not yet recruiting

10 enrolled

Phase 3 Not yet recruiting

Pathologic Complete Response, Head and Neck Neoplasms

NCT07472868 2026-03-16

MEND-IT II

394 enrolled

Pathologic Complete Response

NCT06647680 2026-03-06

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

35 enrolled

Phase EARLY_PHASE1 Active not recruiting

Pathologic Complete Response, Rectal Neoplasms

NCT03832569 2026-03-05

Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors

17 enrolled

Pathologic Complete Response

NCT06130995 2026-03-05

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

Phase 1 Recruiting

46 enrolled

Pathologic Complete Response, Neoplasm, Residual

NCT04055220 2026-02-17

REGOSTA

Phase 2 Not yet recruiting

168 enrolled

Sarcoma

Pathologic Complete Response, Bone Neoplasms, Chondrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Patient Compliance, Sarcoma, Ewing, Osteosarcoma, Histiocytoma, Malignant Fibrous

NCT07397442 2026-02-11

Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer

19 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT07353723 2026-01-20

Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer

10 enrolled

Pathologic Complete Response, Head and Neck Neoplasms

NCT07328841 2026-01-09

Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy

Phase 3 Recruiting

456 enrolled

Nasopharyngeal Carcinoma, Pathologic Complete Response

NCT07328854 2026-01-09

40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma

Phase 3 Recruiting

346 enrolled

Nasopharyngeal Carcinoma, Pathologic Complete Response

NCT01794572 2025-12-12

TOMMY

Phase NA Terminated

13 enrolled 10 charts

Plasma cell

Pathologic Complete Response, Multiple Myeloma, Recurrence

NCT01844986 2025-12-10

SOLO-1

450 enrolled 18 charts 1 FDA

Gynecologic

Pathologic Complete Response, Ovarian Neoplasms

NCT07007052 2025-11-26

TAGVEN

Phase 2 Not yet recruiting

33 enrolled

Myeloid

Pathologic Complete Response, Blastic Plasmacytoid Dendritic Cell Neoplasm

NCT07066189 2025-10-29

Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC

160 enrolled

Pathologic Complete Response, Motor Activity, Triple Negative Breast Neoplasms

NCT04229979 2025-10-01

REGAL

127 enrolled

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT04335669 2025-09-12

NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC

325 enrolled

Phase NA Not yet recruiting

Pathologic Complete Response, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07164872 2025-09-10

Neoadjuvant Chemotherapy Combined With Preoperative Radiotherapy for Locally Advanced Breast Cancer

50 enrolled

Phase NA Active not recruiting

Pathologic Complete Response, Breast Neoplasms

NCT06087718 2025-08-14

Feasibility of the Maastro Applicator in Rectal Cancer

10 enrolled

472 enrolled 24 charts 1 FDA

Pathologic Complete Response, Radiation Injuries, Rectal Neoplasms

NCT06728982 2025-08-01

Impact Of Metformin In Rectal Cancer Patients

Phase 2/3 Completed

85 enrolled

Pathologic Complete Response

NCT01757535 2025-07-08

QUAZAR AML-001

Phase 3 Completed

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT06811844 2025-07-01

Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC

208 enrolled

Pathologic Complete Response, Nasopharyngeal Neoplasms

NCT03522246 2025-06-24

ATHENA

1,097 enrolled 26 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Pathologic Complete Response, Fallopian Tube Neoplasms, Neoplasms

NCT06927180 2025-06-23

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

180 enrolled

Pathologic Complete Response, Breast Neoplasms

NCT05416164 2025-03-26

DESCARTES: De-ESCAlation of RadioTherapy in Patients With Pathologic Complete rESponse to Neoadjuvant Systemic Therapy

595 enrolled

Pathologic Complete Response, Breast Neoplasms

NCT05976815 2025-03-26

KEYMOVE

86 enrolled

LymphoidOther hematologic neoplasm

Pathologic Complete Response, Breast Neoplasms, Motor Activity

NCT04314219 2025-03-13

PTCy-PMAT

Phase 3 Recruiting

264 enrolled

Pathologic Complete Response, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05918328 2025-03-07

Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC

610 enrolled

Pathologic Complete Response, Breast Neoplasms

NCT05350722 2024-12-30

ABLATIVE-2

100 enrolled

Pathologic Complete Response, Breast Neoplasms

NCT06276868 2024-12-17

Darsilide Combined With AI, Trastuzumab and Patuzumab in the Neoadjuvant Treatment of HR+/HER2+ Breast Cancer

71 enrolled

Pathologic Complete Response, Breast Neoplasms

NCT05000697 2024-11-27

CCHOWW

216 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT01266083 2024-11-19

WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

LymphoidOther hematologic neoplasm

22 enrolled 8 charts

Pathologic Complete Response, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04934670 2024-08-27

2002

Phase 3 Terminated

12 enrolled 12 charts

Lymphoid

Pathologic Complete Response, Lymphoma, Follicular

NCT04435197 2024-07-03

PALACE-2

143 enrolled

Esophageal Squamous Cell Carcinoma, Pathologic Complete Response

NCT01340430 2024-05-09

Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer

43 enrolled

Pathologic Complete Response

NCT05659056 2024-04-16

Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer

Phase 2 Unknown

65 enrolled

Phase 2 Active not recruiting

Pathologic Complete Response, Breast Neoplasms

NCT01686334 2024-03-12

WIDEA

130 enrolled

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT05474690 2024-02-26

A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Phase 3 Withdrawn

Pathologic Complete Response, Breast Neoplasms

NCT02789254 2023-12-28

FLYSYN-101

Phase 1/2 Completed

31 enrolled

Pathologic Complete Response, Leukemia, Leukemia, Myeloid, Acute

NCT05103293 2023-12-27

PTC Guiding Neoadjuvant Treatment in Breast Cancer

86 enrolled

BreastOther neoplasm

Pathologic Complete Response, Breast Neoplasms, Pathological Conditions, Signs and Symptoms

NCT06180863 2023-12-26

Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients

Phase 2 Withdrawn

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT03125343 2023-11-07

WoW

400 enrolled

Pathologic Complete Response, Rectal Neoplasms

NCT05684874 2023-10-30

SarQuantIRM

Phase NA Unknown

25 enrolled

Sarcoma

Pathologic Complete Response, Neoplasms, Sarcoma

NCT05371860 2023-09-22

Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response

Phase 2 Withdrawn

Pathologic Complete Response, Breast Neoplasms

NCT04126590 2023-09-01

Phase I Study of KN044 in Locally Advanced/Metastatic Solid Tumors

Phase 1 Unknown

39 enrolled

Pathologic Complete Response

NCT05763992 2023-05-18

BREAKFAST-2

Phase 2 Unknown

145 enrolled